Back to Search Start Over

Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.

Authors :
Kondo Y
Ichinose J
Ninomiya H
Hashimoto K
Matsuura Y
Nakao M
Ishikawa Y
Okumura S
Satoh Y
Mun M
Source :
Interactive cardiovascular and thoracic surgery [Interact Cardiovasc Thorac Surg] 2022 Jul 09; Vol. 35 (2).
Publication Year :
2022

Abstract

Objectives: This study aimed to evaluate the prognostic impact of the combination of epidermal growth factor receptor (EGFR) mutation and the presence of high-grade patterns (solid or micropapillary component) in resected stage I lung adenocarcinoma.<br />Methods: Patients who underwent curative resection for pathological stage I lung adenocarcinoma and EGFR mutation analysis were included in this study. The impact of the combination of EGFR mutation and the presence of >5% high-grade patterns on recurrence-free survival (RFS) was retrospectively analysed using Cox proportional hazards model and propensity score-matched analysis.<br />Results: Among the included 721 patients, EGFR mutations were positive in 380 (52.7%). In the EGFR-mutated group, cases with high-grade patterns showed poorer RFS than those without (5-year RFS, 77.7% vs 92.5%, P < 0.001), whereas there were no significant prognostic differences in the EGFR wild-type group (5-year RFS, 89.8% vs 88.2%, P = 0.807). Multivariable analyses revealed that the combination of EGFR mutations and the presence of high-grade patterns was associated with poor RFS (hazard ratio = 1.655, P = 0.035). Furthermore, EGFR mutation was associated with poor RFS in the group with high-grade patterns (hazard ratio = 2.108, P = 0.008). After propensity score matching, EGFR-mutated cases with high-grade patterns showed poorer RFS (P = 0.028).<br />Conclusions: The combination of EGFR mutation and the presence of high-grade patterns was associated with recurrence in resected stage I lung adenocarcinoma. Histological subtypes, including minor components, should be considered when evaluating the risk of recurrence in patients with EGFR-mutated lung adenocarcinoma.<br /> (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.)

Details

Language :
English
ISSN :
1569-9285
Volume :
35
Issue :
2
Database :
MEDLINE
Journal :
Interactive cardiovascular and thoracic surgery
Publication Type :
Academic Journal
Accession number :
35266536
Full Text :
https://doi.org/10.1093/icvts/ivac062